A study of patients with ankylosing spondylitis starting their first TNF inhibitor found that those who stayed on the treatment for at least 2 years had a median drug survival period of 10.6 years, with 24% discontinuing. The most common reason for discontinuation was inefficacy, followed by clinical remission and adverse events. Patients receiving different types of TNF inhibitors had varying rates of discontinuation based on different factors. Overall, the study highlighted the need for personalized treatment approaches and further research to optimize patient outcomes in the treatment of ankylosing spondylitis.
Source link
Median survival of first-line TNF inhibitor in ankylosing spondylitis nearly 11 years
